IMPACT OF TAFAMIDIS USE IN COLOMBIAN PATIENTS DIAGNOSED WITH ATTR-CM ON HEALTH-RELATED QUALITY OF LIFE DURING TWO YEARS OF FOLLOW-UP: REAL WORLD STUDY IN COLOMBIA
Author(s)
Juan M. Reyes, MSc1, Nilson Lopez, MD2, Juan Molina, MD1, Maria J. Rodriguez, MD3, Gustavo Ortega, MD4, Mónica García, Therapeutist5, Andreina J. Alamo, BSc1, Gina Gonzalez, MD6, Nelson Murillo, MD7, Eduardo Echeverry, MD8, Orlando Castaño, MD9, Juan Lopez, MD10;
1Pfizer SAS, Bogotá, Colombia, 2Hospital Pablo Tobón Uribe, Medellín, Colombia, 3Fundación Cardioinfantil, Bogotá, Colombia, 4Sura IPS, Barranquilla, Colombia, 5Pfizer, Bogota, Colombia, 6Fundación Santa fe de Bogotá, Bogotá, Colombia, 7Clínica de Occidente, Cali, Colombia, 8Clínica Imbanaco, Cali, Colombia, 9Colsanitas, Cali, Colombia, 10Fundación Valle del Lili-Centro de investigaciones clínicas, Cali, Colombia
1Pfizer SAS, Bogotá, Colombia, 2Hospital Pablo Tobón Uribe, Medellín, Colombia, 3Fundación Cardioinfantil, Bogotá, Colombia, 4Sura IPS, Barranquilla, Colombia, 5Pfizer, Bogota, Colombia, 6Fundación Santa fe de Bogotá, Bogotá, Colombia, 7Clínica de Occidente, Cali, Colombia, 8Clínica Imbanaco, Cali, Colombia, 9Colsanitas, Cali, Colombia, 10Fundación Valle del Lili-Centro de investigaciones clínicas, Cali, Colombia
OBJECTIVES: To describe the impact of tafamidis use on quality of life and hospitalization rates in Colombian patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) both hereditary and wild-type over a two-years follow-up period.
METHODS: This was a non-interventional, descriptive, longitudinal, prospective study. Eligible patients had a confirmed diagnosis of ATTR-CM both hereditary and wild-type and prescribed tafamidis prior to enrollment were recruited. Follow-up began on the index date (first tafamidis prescription) and continued until one of the following occurred: patient death, withdrawal from the study, treatment discontinuation, loss to follow-up, or completion of 24 months of follow-up. Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Hospitalization frequency and cardiovascular medication use were also recorded. Patients were contacted every three months by phone calls through validated questionnaires and structured interviews.
RESULTS: Thirty-two patients were enrolled in the study. The mean of follow-up was 21.6 months. The mean age was 75.1 ± 6.7 years, and most were male (84.4%). ATTR wild type was the most frequent subtype (59.4%). According to the New York Heart Association (NYHA) classification, 12 patients were in class II, 9 in class III, and 8 in class I and 3 without data. During follow-up, ten patients experienced at least one hospitalization (31.3%), accounting for a total of 13 events, eight of which were due to cardiovascular causes. Four patients required cardiovascular devices. All domains of the Kansas City Cardiomyopathy Questionnaire (KCCQ) improved during follow-up. The domains with the most significant changes were symptom frequency, self-efficacy, total symptoms, social limitations, clinical summary, and symptom burden. Domain scores stabilized after approximately 13-15 months of follow-up.
CONCLUSIONS: Tafamidis was associated to increase the quality of life, improvement of symptoms, social limitations, and low frequency of cardiovascular hospitalizations in a Colombian patients diagnosed by ATTR-CM. The results were consistent with ATTR-ACT study.
METHODS: This was a non-interventional, descriptive, longitudinal, prospective study. Eligible patients had a confirmed diagnosis of ATTR-CM both hereditary and wild-type and prescribed tafamidis prior to enrollment were recruited. Follow-up began on the index date (first tafamidis prescription) and continued until one of the following occurred: patient death, withdrawal from the study, treatment discontinuation, loss to follow-up, or completion of 24 months of follow-up. Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Hospitalization frequency and cardiovascular medication use were also recorded. Patients were contacted every three months by phone calls through validated questionnaires and structured interviews.
RESULTS: Thirty-two patients were enrolled in the study. The mean of follow-up was 21.6 months. The mean age was 75.1 ± 6.7 years, and most were male (84.4%). ATTR wild type was the most frequent subtype (59.4%). According to the New York Heart Association (NYHA) classification, 12 patients were in class II, 9 in class III, and 8 in class I and 3 without data. During follow-up, ten patients experienced at least one hospitalization (31.3%), accounting for a total of 13 events, eight of which were due to cardiovascular causes. Four patients required cardiovascular devices. All domains of the Kansas City Cardiomyopathy Questionnaire (KCCQ) improved during follow-up. The domains with the most significant changes were symptom frequency, self-efficacy, total symptoms, social limitations, clinical summary, and symptom burden. Domain scores stabilized after approximately 13-15 months of follow-up.
CONCLUSIONS: Tafamidis was associated to increase the quality of life, improvement of symptoms, social limitations, and low frequency of cardiovascular hospitalizations in a Colombian patients diagnosed by ATTR-CM. The results were consistent with ATTR-ACT study.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR1
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Geriatrics